Search Results

Archerfish Precision Diagnostics is dedicated to improving patient care by offering cutting-edge diagnostic solutions to doctors. About Us Our Mission Archerfish Precision Diagnostics is dedicated to improving patient care by offering cutting-edge diagnostic solutions to doctors. Levering on our robust capabilities in development and commercialisation, we consistently innovate to address the changing requirements of the regional healthcare ecosystem. We Believe in The Power of a Team Dr Lim Cheok Peng Chairman Mr Peter Chia Director Dr Cheong Wei Yang Director A respected cardiologist, Dr Lim is the co-founder of Angsana Laboratory. He was previously the CEO of Parkway Holdings and Managing Director of IHH Healthcare Berhad. Dr Lim sits on the board of several companies including Singhealth and Kidney Dialysis Foundation. His extensive experience cements his influence in the healthcare sector. Mr. Peter Chia is the Director and Chief Executive Officer at Temasek Life Sciences Laboratory and Temasek Life Sciences Accelerator (TLA). He plays a key role in the establishment of many significant research collaborations with the industry, the commercialisation of TLL research technologies and creation of spin-offs. Dr Cheong Wei Yang is serving as Senior Adviser at the Ministry of Health Health Economics division. He formulates health economics models for new technologies in collaboration with academia. He also hold the position of Vice Provost (Strategic Research Partnerships) at Singapore Management University , where they develop and implement strategic research partnerships with government and industry. Dr Cheong's expertise bridges the gap between academic research, government policy, and industry innovation. Dr Ian Cheong Director Dr Chris Tan Group Chief Executive Officer Dr. Ian Cheong is a pioneering scientist and entrepreneur, co-founding Pathnova Laboratories to revolutionise nasopharyngeal cancer detection through AI-enhanced serology , currently demonstrated in a large-scale Singaporean study. His innovative work spans multiple domains, including developing a novel algorithmic approach for cancer mutation identification and discovering a unique tumor-targeting bacterial property for chemotherapy delivery. A distinguished researcher, he holds a PhD from Johns Hopkins and has received numerous awards, reflecting his significant contributions to molecular pathogenesis , genetics, genomics, and cancer therapeutics. Dr Chris Tan is the Group CEO of Archerfish DX and co-founder of Angsana Laboratory. Under his stewardship for Angsana, he grew the business to become the leading molecular oncology provider in Asia and achieved CAP accreditation. He is a seasoned executive with a strong track record in the life sciences and diagnostics sectors, demonstrated by leadership roles at companies like SomaLogic, and Twist Bioscience. He has a proven ability to build and scale commercial operations in the APAC region, including establishing new entities and driving significant revenue growth. Dr Benedict Yan Chief Medical Officer Dr Benedict Yan is the Chief Medical Officer of Archerfish Precision Diagnostics. He is also the CGO of Pathnova and other clinical laboratories in Singapore. He was the former Head of the Molecular Diagnosis Centre at NUH. He is also an Adjunct Associate Professor with the Department of Paediatrics at the Yong Loo Lin School of Medicine, NUS. At NUH, he led the development of several molecular assays, including the first myeloid neoplasm NGS assay in Singapore. He also contributed to the setting up of the clinical COVID-19 PCR laboratory at A*STAR. He has published widely in the fields of pathology and molecular diagnostics. Mr Jason Foo Group Chief Operating Officer Jason Foo serves as Group Chief Operating Officer of Archerfish Precision Diagnostics and concurrently holds the roles of CEO and Director of Pathnova Laboratories. Previously, as COO, he was instrumental in driving operational excellence and cultivating a performance-oriented culture focused on action and measurable outcomes. He brings a distinguished record of global healthcare leadership, including prior experience as an Executive Director at a multinational medical device corporation with operations across 10 countries, and as a Vice President of Sales responsible for global healthcare strategy. Jason holds an MBA from the University of Stirling and was awarded the Public Service Medal (PBM) by Singapore’s Prime Minister’s Office for his outstanding contributions during the COVID-19 pandemic. Mr Kevin Lee Group Chief Financial Officer Kevin Lee is the Group CFO of Archerfish Precision Diagnostics. He is concurrently the CEO of Angsana Molecular & Diagnostics Laboratory. Kevin was also previously Group COO and CFO of various regional healthcare groups where he was responsible for the overall strategy and direction of the business. Prior to taking his healthcare leadership roles, Kevin also spent more than 20 years in investment banking and strategy consulting. Kevin is a Fellow Chartered Accountant, an ASEAN CPA and holds an MBA from Warwick Business School, UK. Kevin is also on the board of Renal Health Services Limited, a charity that supports kidney health in Singapore, and on the finance committee of Catholic Pre-school Education (Singapore) Ltd, a non-profit that manages preschools in Catholic parishes. Our History Fo rmed in 2025, Archerfish Precision Diagnostics was incepted from the strategic merger of two industry leaders: Angsana Molecular and Diagnostics Laboratory and Pathnova Laboratories . Angsana is a pioneer in the field of molecular oncology in Asia, having introduced clinical Next-Generation Sequencing (NGS) early on. They have a strong track record of successful commercialization and bringing clinical diagnostics tests to the market. Pathnova specializes in the development and manufacturing of diagnostic products, including the creation of intellectual property related to novel diagnostic technologies, exemplified by their proprietary early screening test for nasopharyngeal cancer. Recognizing the immense potential for synergy, these two powerhouses joined forces, creating a unified entity with a clear vision: to address the specific healthcare needs of the Asian community. This merger was not merely a consolidation of resources; it was a fusion of expertise, a blending of innovation and commercial acumen. Archerfish DX, built on the foundations of Angsana's commercial success and Pathnova's scientific excellence, is now dedicated to accelerating the development and accessibility of affordable diagnostics, ensuring that the fruits of scientific advancement reach the patients who need them most across Asia. Our Facilities Angsana Molecular & Diagnostics Laboratory 67 Ubi Avenue 1, #06-06, Innovate@Ubi North Wing, Singapore 408942 www.angsanalabs.com Pathnova Laboratories 1 Research Link, #05-40, Singapore 117604 www.pathnova.com

ArcherfishDX is equipped to support clinical research and trials tailored to specific needs of our partners. Contact Us First Name Last Name Phone Our team may use this number to contact you about your inquiry Email Company Inquiry Send Thanks for submitting!

Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced News & Resources Archerfish Precision Diagnostics and C2N Diagnostics Announce Strategic Collaboration to Bring Advanced Alzheimer's Diagnostic Testing to Singapore and Across Asia 24 July 2025, Singapore Archerfish Precision Diagnostics (Archerfish), a premier diagnostic laboratory serving Singapore and the broader Asian region and C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics, today announced a strategic partnership to introduce and expand access to C2N's innovative blood-based diagnostic test for Alzheimer's Disease (AD). This collaboration marks a significant step forward in improving early and accurate diagnosis of AD, a critical need across Asia. The partnership will leverage Archerfish's extensive network and expertise in laboratory services and patient outreach throughout Singapore and other key Asian markets. This will facilitate the widespread availability of C2N's cutting-edge PrecivityAD2™ blood test, which offers a less invasive and more accessible method for detecting amyloid pathology in the brain, a hallmark of AD, all through a single blood draw. Embracing breakthrough technology in Alzheimer’s Disease diagnostics This innovative diagnostic test is the first of its kind in Singapore and signals a step towards more accessible, non-invasive AD diagnostics. The PrecivityAD2™ blood test is intended for individuals 55 and older who are being evaluated by a healthcare provider for AD or other causes of cognitive decline. Using high resolution liquid chromatography, tandem mass spectrometry, PrecivityAD2™ detects specific amyloid beta and tau peptides circulating in blood that are associated with the presence of amyloid plaques in the brain that can aid healthcare providers in the diagnosis of AD. Early and accurate diagnosis of AD is paramount for several reasons: it allows patients and their families to plan for the future, access appropriate care and support services, and potentially enrol in clinical trials for emerging therapies. Traditional diagnostic methods can be invasive, costly, and often inaccessible in many regions. C2N's PrecivityAD2™ blood test aims to overcome these barriers, providing a more convenient and scalable solution. Addressing Alzheimer’s Disease in Singapore’s Ageing Population In light of a rapidly ageing population, this partnership seeks to strengthen local capabilities for AD diagnosis. Currently, approximately 1 in 11 adults aged 60 years and over suffer from dementia, including AD¹. By 2030, around 1 in 4 citizens (24.1%) will be aged 65 & above.² Given that the risk of dementia increases with age, Singapore will likely see a rise in the number of cases as her population continues to age, highlighting the need for accessible yet highly accurate diagnostic tools such as PrecivityAD2™. While cognitive issues may have many potential causes, the PrecivityAD2™ blood test can provide greater clarity in an AD diagnosis. The PrecivityAD2™ test result is a clinically validated algorithm that can either confirm the presence of amyloid pathology and increase confidence in an AD diagnosis to enable patients to take timely action to manage their condition or rule out AD as a cause for cognitive decline, thus avoiding additional rounds of testing and accelerating a timely intervention. In either case, PrecivityAD2™ empowers healthcare providers and patients to improve healthcare outcomes through increased diagnostic certainty. “We are delighted to partner with Archerfish to bring our advanced AD diagnostic solution to patients and clinicians in Singapore and across Asia,” said Joel Braunstein, CEO and President of C2N. “This collaboration aligns with our mission to transform brain health by providing innovative, accessible, and reliable diagnostic tools. Archerfish's deep understanding of the regional healthcare landscape and their commitment to excellence make them an ideal partner to help us address the growing burden of Alzheimer's disease in this part of the world.” Dr Chris Tan, Group Chief Executive Officer, Archerfish Precision Diagnostics commented, “Archerfish is committed to bringing the most advanced and impactful diagnostic technologies to our patients. The partnership with C2N Diagnostics represents a pivotal moment in our efforts to combat AD in Asia. We believe that C2N’s PrecivityAD2™ will revolutionize how AD is diagnosed, enabling earlier intervention and better patient outcomes. We look forward to working closely with C2N to ensure broad access to this vital test.” “Accurate and accessible diagnosis is an important cornerstone in the management of Alzheimer’s Disease. With advances in blood-based biomarkers, we are seeing new possibilities that complement standard diagnostic methods and support more timely clinical decision-making. Such developments hold promise for improving care for individuals experiencing cognitive decline,” said Professor Christopher Chen, Director, Memory Aging and Cognition Centre, National University Health System. About Archerfish Precision Diagnostics Archerfish Precision Diagnostics is a company focused on developing and launching novel diagnostic tests that address the unique healthcare requirements of the Asian community. It leverages an expert team comprising leading scientists, healthcare administrators, and molecular pathologists to unify first-in-class diagnostics and introduce them to Singapore and the broader Asian market. Formed through the merger of Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, both CAP-accredited laboratories, Archerfish combines excellence in clinical laboratory practice with a strong commitment to research and development. About C2N Diagnostics C2N Diagnostics is a U.S-based specialty diagnostics company dedicated to advancing the field of brain health through cutting-edge diagnostic technology. Their innovative products and services enhance patient care and support clinical trials for neurodegeneration treatment. With strong foundations in scientific research and global clinical partnerships, C2N remains committed to transforming the way brain disorders are diagnosed, understood, and treated around the world. Contact Information Archerfish Precision Diagnostics Angeline Wong angeline.wong@archerfishdx.com C2N Diagnostics Joni Henderson joni.henderson@c2n.com ¹ Subramaniam M, Abdin E, Asharani PV, Roystonn K, Devi F, Peizhi W, et al. Prevalence of dementia in Singapore: Changes across a decade. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2025;21(2):10.1002/alz.14485. https://pubmed.ncbi.nlm.nih.gov/39868432/ ² https://www.population.gov.sg/files/media-centre/publications/population-in-brief-2023.pdf Archerfish Precision Diagnostics and C2N Diagnostics Announce Strategic Collaboration to Bring Advanced Alzheimer's Diagnostic Testing to Singapore and Across Asia Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics View All Blog Posts

Archerfish Precision Diagnostics DX is dedicated to improving patient care by offering cutting-edge diagnostic solutions to doctors. Levering on our robust capabilities in development and commericialisation, we consistently innovate to address the changing requirements of the regional healthcare ecosystem. Precision Diagnostics A Brighter Future At Archerfish Precision Diagnostics, we are committed to revolutionising healthcare through precise, adaptable, and scientifically driven diagnostic solutions About Us Empowering Healthcare, Improving Lives. We deliver accurate and meaningful insights that empower healthcare providers to make informed decisions and improve patient outcomes. Read More Our Services Molecular Oncology Next-Generation-Sequencing (NGS) sequences numerous genes simultaneously to identify genetic mutations in a tumor, helping to personalise cancer treatment. View Service Allergy and Molecular Allergology Diagnostic services using advanced molecular techniques to identify specific allergens and components, enabling precise and personalised allergy management. View Service Nasopharyngeal Carcinoma (NPC) Screening Early detection screening for nasopharyngeal cancer aims to identify the disease at its earliest, most treatable stages. View Service

The website is under construction We will be right back!

Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced News & Resources Newly-formed Archerfish Precision Diagnostics Pte Ltd : Ushers a New Era in Advanced Diagnostics 04 March 2025, Singapore In picture: From left: Dr Ian Cheong, Mr Peter Chia, Dr Chris Tan, Mr Kevin Lee In a significant development for the clinical diagnostics landscape in Singapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to form Archerfish Precision Diagnostics Private Limited (Archerfish) . This strategic union brings together two leading laboratory players with complementary expertise – Angsana in molecular diagnostics and Pathnova in serology and AI – This merger positions Archerfish as a powerhouse in advanced diagnostic solutions. The merger seeks to combine the unique strengths of both laboratories, expanding their capabilities beyond their current portfolio to offer a comprehensive range of advanced diagnostic assays. Angsana is a pioneer in the field of molecular oncology in Asia, having introduced clinical Next-Generation Sequencing (NGS) early on. They have a strong track record of successful commercialisation and bringing clinical diagnostics tests to the market. Pathnova specialises in the development and manufacturing of diagnostic products, including the creation of intellectual property related to novel diagnostic technologies, exemplified by their proprietary early screening test for nasopharyngeal cancer. Both labs are focused on diseases prevalent in Asia. Archerfish will cater to both the private and public healthcare sectors, enhancing access to innovative and accurate diagnostic services. Advancing Diagnostic Innovation Archerfish's vision is to be at the forefront of diagnostic innovation, providing accurate, timely, and comprehensive solutions for early cancer screening, as well as precision diagnostics guiding treatments for cancer and other diseases. By leveraging cutting-edge technologies and pioneering research, the company is expanding its portfolio of diagnostic tests to drive innovation in clinical practice. Next-Generation Sequencing One key area of development is advancing Next-Generation Sequencing (NGS) beyond personalized cancer care to other areas including infectious disease detection. For instance, metagenomic NGS (mNGS) enables the comprehensive identification of microorganisms, offering the potential to detect a wide range of viral and bacterial infections from a single plasma sample within a clinically actionable timeframe. Data-Driven Disease Detection In addition, the company is developing data-driven approaches to disease detection through serum proteomics and serological profiling. Advances in aptamer technology now allow for the profiling of thousands of proteins in serum, providing a versatile and powerful tool for diverse diagnostic applications. Artificial Intelligence To maximise the potential of these data-driven methods, Archerfish is integrating artificial intelligence to refine pattern analysis, improving disease detection and predictive accuracy. Through these innovations, the company remains committed to transforming diagnostics and enhancing patient outcomes. The above contains forward-looking statements that are subjected to further technology and market research. Strategic Leadership and Investment Archerfish's management team comprises leading clinicians, scientists and accomplished healthcare executives, providing the vision and leadership necessary for the company's growth. Their combined expertise in diagnostics, research, and business strategy aims to keep Archerfish at the industry's forefront in Asia. The merger is backed by a consortium of strategic investors including Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, Temasek Life Sciences Accelerator and SEEDS Capital, which fund and support research and innovation. With such backing, Archerfish is well positioned to achieve its ambitious goals. Collaborative Efforts and Future Plans The formation of Archerfish is expected to facilitate greater collaboration in public-private partnerships, contributing to healthcare cost efficiency through economies of scale. By working closely with government agencies and healthcare providers, Archerfish aims to improve access to high-quality diagnostic services. Archerfish is seeking to raise at least SGD$50 million over the next three years to support its expansion plans. This funding will be used to further develop and commercialise its innovative diagnostic solutions as well as regional expansion. "This merger represents a significant step forward in our mission to advance diagnostic science and improve patient outcomes," said Dr. Lim Cheok Peng, Chairman of Archerfish Precision Diagnostics, Founder of Angsana Molecular & Diagnostics Laboratory. "Archerfish will address a critical gap in Singapore’s clinical laboratory landscape, seamlessly translating scientific evidence into practical, high-quality clinical laboratory solutions," added Dr. Ian Cheong, Director of Archerfish Precision Diagnostics and Co-founder of PathNova Laboratories. "The merger of these two laboratories fosters a dynamic synergy, uniting expertise and resources to drive groundbreaking innovation and create a greater positive impact on society," said Mr Peter Chia, CEO of Temasek Lifesciences Laboratory. About Archerfish Precision Diagnostics Archerfish Precision Diagnostics Private Limited is a leading molecular diagnostics company dedicated to innovative solutions for cancer detection and treatment. Formed through the merger of Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, both CAP-accredited laboratories, Archerfish combines excellence in clinical laboratory practice with a strong commitment to research and development. Contact Information Angeline Wong Senior Strategic Development Manager angeline.wong@archerfishdx.com In picture: Standing from left: Dr Brendan Pang, Dr Benedict Yan, Dr Brian Wang, Mr Jason Foo, Dr Venkateswaran Natarajan. Seated from left: Dr Ian Cheong, Dr Lim Cheok Peng, Mr Kevin Lee

Next-Generation-Sequencing (NGS) sequences numerous genes simultaneously to identify genetic mutations in a tumor, helping to personalise cancer treatment. Our Services Laboratory & Research Molecular Oncology Next-Generation-Sequencing (NGS) sequences numerous genes simultaneously to identify genetic mutations in a tumor, helping to personalise cancer treatment. View Service Allergy and Molecular Allergology Diagnostic services using advanced molecular techniques to identify specific allergens and components, enabling precise and personalised allergy management. View Service Nasopharyngeal Carcinoma (NPC) Screening Early detection screening for nasopharyngeal cancer aims to identify the disease at its earliest, most treatable stages View Service Contract Research ArcherfishDX is equipped to support clinical research and trials tailored to specific needs of our partners. Contact Us Consulting Services and Partnership We can offer a unique blend of scientific expertise and collaborative partnerships to help you achieve your research and development goals. Contact Us